CN106343463A - Royal jelly and beeswax lozenge and preparation method thereof - Google Patents
Royal jelly and beeswax lozenge and preparation method thereof Download PDFInfo
- Publication number
- CN106343463A CN106343463A CN201610707244.2A CN201610707244A CN106343463A CN 106343463 A CN106343463 A CN 106343463A CN 201610707244 A CN201610707244 A CN 201610707244A CN 106343463 A CN106343463 A CN 106343463A
- Authority
- CN
- China
- Prior art keywords
- powder
- royal jelly
- cera flava
- lac regis
- regis apis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940109850 royal jelly Drugs 0.000 title claims abstract description 42
- 235000013871 bee wax Nutrition 0.000 title abstract description 9
- 239000012166 beeswax Substances 0.000 title abstract description 9
- 239000007937 lozenge Substances 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 51
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940038481 bee pollen Drugs 0.000 claims abstract description 19
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 19
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000008014 freezing Effects 0.000 claims abstract description 14
- 238000007710 freezing Methods 0.000 claims abstract description 14
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000811 xylitol Substances 0.000 claims abstract description 14
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 14
- 229960002675 xylitol Drugs 0.000 claims abstract description 14
- 235000010447 xylitol Nutrition 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 239000007766 cera flava Substances 0.000 claims description 57
- 241000256836 Apis Species 0.000 claims description 47
- 229940046011 buccal tablet Drugs 0.000 claims description 25
- 239000006189 buccal tablet Substances 0.000 claims description 25
- 239000008176 lyophilized powder Substances 0.000 claims description 21
- 239000008187 granular material Substances 0.000 claims description 12
- 241000256844 Apis mellifera Species 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 10
- 239000013078 crystal Substances 0.000 claims description 6
- 238000002203 pretreatment Methods 0.000 claims description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 230000035764 nutrition Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract 2
- 238000002844 melting Methods 0.000 abstract 2
- 230000008018 melting Effects 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 238000005498 polishing Methods 0.000 abstract 1
- 230000005195 poor health Effects 0.000 abstract 1
- 238000003825 pressing Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- QHBZHVUGQROELI-UHFFFAOYSA-N Royal Jelly acid Natural products OCCCCCCCC=CC(O)=O QHBZHVUGQROELI-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- QHBZHVUGQROELI-SOFGYWHQSA-N (E)-10-hydroxydec-2-enoic acid Chemical compound OCCCCCCC\C=C\C(O)=O QHBZHVUGQROELI-SOFGYWHQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AUNGANRZJHBGPY-MBNYWOFBSA-N 7,8-dimethyl-10-[(2R,3R,4S)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-MBNYWOFBSA-N 0.000 description 1
- 241000256846 Apis cerana Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000000203 Salix gracilistyla Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a royal jelly and beeswax lozenge and a preparation method thereof, and relates to health care food. The problems of acor mouthfeel, easy melting and poor health care effect of the existing royal jelly lozenge are solved. The royal jelly and beeswax lozenge is prepared from the following ingredients including 81.7 to 87.3 percent of royal jelly freeze dry powder, 5.9 to 8.7 percent of beeswax powder, 3 to 6 percent of bee pollen, 2 to 4 percent of fruit powder, 0.5 to 1.3 percent of xylitol and 0.1 to 0.3 percent of citric acid. The preparation method comprises the preparation steps of (1) fast freezing royal jelly; performing crushing to obtain the royal jelly freeze dry powder; freezing the beeswax; performing crushing to obtain the beeswax powder; (2) uniformly mixing the royal jelly freeze dry powder, the beeswax powder, the bee pollen and the fruit powder; adding the xylitol and the citric acid; uniformly stirring the mixture by absolute ethyl alcohol to obtain a whole particle; (3) pressing the whole particle into a tablet; performing polishing to obtain a finished product. The royal jelly freeze dry powder is contained in the ingredients; the bee pollen and the fruit powder are also added; meanwhile, the beeswax is added, so that the acor mouthfeel of the royal jelly is improved; the melting time in the mouth is prolonged; the absorption by a human body is easy; the nutrition and health care effects are improved.
Description
Technical field
The present invention relates to health food and its production method are and in particular to a kind of royal jelly Cera Flava buccal tablet and preparation method thereof.
Background technology
Lac regis apis (royal jelly), also known as Lac regis apiss, Lac regis apis breast, queen bee breast, Lac regis apis, abbreviation royal jelly.It is in honeycomb
Cultivate the lingual gland (i.e. hypopharyngeal gland) of young Worker head of larva and the mixture of maxillary glandular secretion, be creamy white or light yellow,
There is sour and astringent, acid, micro- sweet and there is special aroma, be supplied with becoming the food of the larva of queen bee, be also that queen bee is lifelong
Food.The chemical analysis of Lac regis apis are complex, in general, moisture content 64.5～69.5%, crude protein 11～14.5%, carbon
Hydrate 13～15%, lipid 6.0%, mineral 0.4～2%, do not determine material 2.84～3.0%.Lac regis apis contain abundant
Vitamin, especially b vitamin is especially many.In addition there are thiamine (b1), riboflavin (b2), pyridoxol (b6), vitamin
B12, nicotinic acid, pantothenic acid, Folic Acid, biotin, inositol, vitamin c, vitamin d etc., wherein 10-HAD (10-
Hda), content is more than 1.4%.Contain this material due to only having in Lac regis apis in nature, so also it is referred to as king
Slurry acid.In addition mineral, ferrum, copper, magnesium, zinc, potassium, sodium etc. are also contained.Modern medicine proves, Lac regis apis have and improve nutrition, benefit
Fill mental, improve body immunity the effects such as, can prophylactic treatment cardiovascular and cerebrovascular disease, to three fat abnormality diseases, sclerosis of blood vessels, the rhythm of the heart
The Diseases such as uneven, diabetes all have good curative effect, can the disease such as auxiliary treatment anemia, there is antiinflammatory, pain relieving, promote wound
Mouth healing.10-hda in Lac regis apis, that is, Royal Jelly acid play the role of antibacterial, antiinflammatory, pain relieving, escherichia coli, suppuration ball can be suppressed
Bacterium, epidermophyton, tubercule bacillus etc. more than ten plant bacterial growth.It is configured to external sliver with royal jelly and Mel on clinical medicine, use
In scald, cold injury, surgery in anus section wound surface, its pain relieving, antiinflammatory, improve wound surface blood circulation and nutrition and other effects and be substantially better than all scholars
The external sliver such as woods, experiment shows, Lac regis apis energy anticancer spreads, and makes cancer cell development degeneration change, to cancer
Disease plays good preventive effect；Can appetite strengthening and absorbability, all have adjustment effect to liver and gastrointestinal function.Lac regis apis
It is a kind of to integrate edible, medicinal, health care natural nourishing product.
At present, domestic bee product buccal tablet species is more, wherein with royal jelly lozenge at most, and there are no Cera Flava so far
The royal jelly lozenge of composition.The royal jelly lozenge mouthfeel of prior art is sour and astringent, is melted and swallows in the short period that keeps in the mouth,
Do not reach the due effect of buccal tablet.
Content of the invention
The purpose of the present invention is intended to overcome the shortcoming of prior art, provides a kind of royal jelly Cera Flava buccal tablet and preparation method thereof,
Solve sour and astringent, the easy thawing of existing royal jelly lozenge mouthfeel, the technical problem of health-care effect difference.
The present invention is achieved through the following technical solutions:
A kind of royal jelly Cera Flava buccal tablet it is characterised in that: described royal jelly Cera Flava buccal tablet consists of the following composition, its weight ratio
For: Lac regis apis lyophilized powder: 81.7～87.3%, Cera Flava powder: 5.9～8.7%, bee pollen: 3～6%, fruit powder: 2～4%, xylose
Alcohol: 0.5～1.3%, citric acid: 0.1～0.3%.
Further, described royal jelly Cera Flava buccal tablet consists of the following composition, and its weight ratio is: Lac regis apis lyophilized powder: 84.5%,
Cera Flava powder: 7.3%, bee pollen: 4%, fruit powder: 3%, xylitol: 0.9%, citric acid: 0.3%.
Further, described fruit powder is Fructus Fragariae Ananssae powder.
A kind of manufacture method of royal jelly Cera Flava buccal tablet it is characterised in that: specifically comprise the following steps that
(1) raw material pre-treatment:
Lac regis apis: by Lac regis apis in -10～-15 DEG C of quick freezings, be then less than the vacuum condition of 4.6mmhg in pressure
Under, after so that the ice crystal in Lac regis apis is directly distilled, pulverize and Lac regis apis lyophilized powder is obtained；
Cera Flava: under the conditions of pure Cera Flava is placed in -10～-15 DEG C, after freezing 12 hours, fast-crushing, 100 mesh sieve, system
Obtain Cera Flava powder；
(2) pelletize: Lac regis apis lyophilized powder, Cera Flava powder, bee pollen, fruit powder mix homogeneously are subsequently adding xylitol, Fructus Citri Limoniae
Acid, then with absolute ethyl alcohol and stirring uniformly, 5～20 mesh sieve, and granulate is progressively obtained；
(3) tabletting: granulate is carried out tabletting, thickness is set as 1.2～1.5mm, pressure is set as 15～20kgf, tabletting
After polish, get product.
Cera Flava used by the present invention, also known as Cera Flava, Apis cerana Fabriciuss, is to be secreted by 4 pairs of wax glands of worker bee abdominal part of the right age in bee colony
A kind of fatty matter, white or light yellow, there is obvious wax fragrance, its main component have acids, free fatty,
Free alkyl alcohol and carbohydrate.Additionally, also carotenoid, vitamin a, aromatic substance etc..The medical value of Cera Flava is non-
Chang Gao, Chinese medicine beeswax has functions that removing toxic substances, granulation promoting, analgesic therapy, and for oral administration and external application can cure mainly pained, dysentery pus and blood of having to go to the toilet, long
Rush down more than, vaginal bleeding due to excessive movement of fetus, carbuncle sore inside fire attack, bursts for a long time and does not holds back, burn due to hot liquid or fire etc..
Bee pollen used by the present invention: in addition to containing protein and aminoacid, also crude fat 8.5%, cellulose 5%.Pollen
In ve, superoxide dismutase (sod), the composition such as selenium can moisten nutrition skin, recover elasticity, the flavone compound energy of skin
Effectively remove the deposition of fat in liver and blood vessel wall, eliminate prostatitis, play antiinflammatory, supporting wound healing, heart tonifying and resist
Atherosclerosis.
Fruit powder used by the present invention is Fructus Fragariae Ananssae powder, and strawberry nutrition enriches, containing Fructose, sucrose, citric acid, malic acid, bigcatkin willow
Acid, aminoacid and the mineral such as calcium, phosphorus, ferrum.In addition it contains multivitamin, especially Determination of Vitamin C are very rich
Richness, just containing 60 milligrams of vitamin c in every 100 grams of Fructus Fragariae Ananssaes.In Fructus Fragariae Ananssae, contained carotene is the important thing of synthetic vitamin a
Matter, has improving eyesight nourishing the liver effect.Fructus Fragariae Ananssae also containing pectin and abundant dietary fiber, can be helped digest, unobstructed stool.With
When, the local flavor of buccal tablet can be improved, allow consumer to be easier to accept.
Used by the present invention, citric acid makees food additive, has gently frank tart flavour.
Compared with current like product, the component of buccal tablet does not only have Lac regis apis lyophilized powder to the present invention, also added bee pollen
And fruit powder, creatively increased Cera Flava component simultaneously, so that product is both kept in the mouth and improve the sour and astringent mouthfeel of Lac regis apis, increase again
Its thawing time in mouth, easily it is absorbed by the body, nutritional health function is improved.The present invention has to be easy to preserve, carries, food
Use the advantages of facilitate.
Specific embodiment
Embodiment 1:
A kind of royal jelly Cera Flava buccal tablet, weighs each raw material by following weight proportions:
Lac regis apis lyophilized powder: 87.3%, Cera Flava powder: 7.1%, bee pollen: 3%, Fructus Fragariae Ananssae powder: 2%, xylitol: 0.5%,
Citric acid: 0.1%.
A kind of making step of royal jelly Cera Flava buccal tablet is as follows:
(1) raw material pre-treatment:
Lac regis apis: by Lac regis apis in -15 DEG C of quick freezings, be then less than in pressure under the vacuum condition of 4.6mmhg, make honeybee
After ice crystal in royal jelly directly distils, pulverize and Lac regis apis lyophilized powder is obtained；
Cera Flava: under the conditions of pure Cera Flava is placed in -15 DEG C, after freezing 12 hours, fast-crushing, 100 mesh sieve, prepared Cera Flava
Powder；
(2) pelletize: Lac regis apis lyophilized powder, Cera Flava powder, bee pollen, fruit powder mix homogeneously are subsequently adding xylitol, Fructus Citri Limoniae
Acid, then with absolute ethyl alcohol and stirring uniformly, 20 mesh sieve, and granulate is progressively obtained；
(3) tabletting: granulate is carried out tabletting, thickness is set as 1.2mm, pressure is set as 20kgf, polish after tabletting, that is,
Obtain finished product.
Embodiment 2:
A kind of royal jelly Cera Flava buccal tablet, weighs each raw material by following weight proportions:
Lac regis apis lyophilized powder: 81.7%, Cera Flava powder: 8.7%, bee pollen: 4%, Fructus Fragariae Ananssae powder: 4%, xylitol: 1.3%,
Citric acid: 0.3%.
A kind of making step of royal jelly Cera Flava buccal tablet is as follows:
(1) raw material pre-treatment:
Lac regis apis: by Lac regis apis in -10 DEG C of quick freezings, be then less than in pressure under the vacuum condition of 4.6mmhg, make honeybee
After ice crystal in royal jelly directly distils, pulverize and Lac regis apis lyophilized powder is obtained；
Cera Flava: under the conditions of pure Cera Flava is placed in -10 DEG C, after freezing 12 hours, fast-crushing, 100 mesh sieve, prepared Cera Flava
Powder；
(2) pelletize: Lac regis apis lyophilized powder, Cera Flava powder, bee pollen, fruit powder mix homogeneously are subsequently adding xylitol, Fructus Citri Limoniae
Acid, then with absolute ethyl alcohol and stirring uniformly, 5 mesh sieve, and granulate is progressively obtained；
(3) tabletting: granulate is carried out tabletting, thickness is set as 1.5mm, pressure is set as 15kgf, polish after tabletting, that is,
Obtain finished product.
Embodiment 3:
A kind of royal jelly Cera Flava buccal tablet, weighs each raw material by following weight proportions:
Lac regis apis lyophilized powder: 84.5%, Cera Flava powder: 7.3%, bee pollen: 4%, fruit powder: 3%, xylitol: 0.9%, lemon
Lemon acid: 0.3%.
A kind of making step of royal jelly Cera Flava buccal tablet is as follows:
(1) raw material pre-treatment:
Lac regis apis: by Lac regis apis in -13 DEG C of quick freezings, be then less than in pressure under the vacuum condition of 4.6mmhg, make honeybee
After ice crystal in royal jelly directly distils, pulverize and Lac regis apis lyophilized powder is obtained；
Cera Flava: under the conditions of pure Cera Flava is placed in -13 DEG C, after freezing 12 hours, fast-crushing, 100 mesh sieve, prepared Cera Flava
Powder；
(2) pelletize: Lac regis apis lyophilized powder, Cera Flava powder, bee pollen, fruit powder mix homogeneously are subsequently adding xylitol, Fructus Citri Limoniae
Acid, then with absolute ethyl alcohol and stirring uniformly, 10 mesh sieve, and granulate is progressively obtained；
(3) tabletting: granulate is carried out tabletting, thickness is set as 1.3mm, pressure is set as 17kgf, polish after tabletting, that is,
Obtain finished product.
Embodiment 4:
A kind of royal jelly Cera Flava buccal tablet, weighs each raw material by following weight proportions:
Lac regis apis lyophilized powder: 85.3%, Cera Flava powder: 5.9%, bee pollen: 6%, fruit powder: 2%, xylitol: 0.5%, lemon
Lemon acid: 0.3%.
A kind of making step of royal jelly Cera Flava buccal tablet is as follows:
(1) raw material pre-treatment:
Lac regis apis: by Lac regis apis in -13 DEG C of quick freezings, be then less than in pressure under the vacuum condition of 4.6mmhg, make honeybee
After ice crystal in royal jelly directly distils, pulverize and Lac regis apis lyophilized powder is obtained；
Cera Flava: under the conditions of pure Cera Flava is placed in -13 DEG C, after freezing 12 hours, fast-crushing, 100 mesh sieve, prepared Cera Flava
Powder；
(2) pelletize: Lac regis apis lyophilized powder, Cera Flava powder, bee pollen, fruit powder mix homogeneously are subsequently adding xylitol, Fructus Citri Limoniae
Acid, then with absolute ethyl alcohol and stirring uniformly, 10 mesh sieve, and granulate is progressively obtained；
(3) tabletting: granulate is carried out tabletting, thickness is set as 1.3mm, pressure is set as 17kgf, polish after tabletting, that is,
Obtain finished product.
Claims (4)
1. a kind of royal jelly Cera Flava buccal tablet it is characterised in that: described royal jelly Cera Flava buccal tablet consists of the following composition, and its weight ratio is:
Lac regis apis lyophilized powder: 81.7～87.3%, Cera Flava powder: 5.9～8.7%, bee pollen: 3～6%, fruit powder: 2～4%, xylitol:
0.5～1.3%, citric acid: 0.1～0.3%.
2. a kind of royal jelly Cera Flava buccal tablet according to claim 1 it is characterised in that: described royal jelly Cera Flava buccal tablet is by following one-tenth
It is grouped into, its weight ratio is: Lac regis apis lyophilized powder: 84.5%, Cera Flava powder: 7.3%, bee pollen: 4%, fruit powder: 3%, xylose
Alcohol: 0.9%, citric acid: 0.3%.
3. a kind of royal jelly Cera Flava buccal tablet according to claim 1 it is characterised in that: described fruit powder is Fructus Fragariae Ananssae powder.
4. a kind of royal jelly Cera Flava buccal tablet according to claims 1 to 3 manufacture method it is characterised in that: concrete steps are such as
Under:
(1) raw material pre-treatment:
Lac regis apis: by Lac regis apis in -10～-15 DEG C of quick freezings, be then less than in pressure under the vacuum condition of 4.6mmhg, make
After ice crystal in Lac regis apis directly distils, pulverize and Lac regis apis lyophilized powder is obtained；
Cera Flava: under the conditions of pure Cera Flava is placed in -10～-15 DEG C, after freezing 12 hours, fast-crushing, 100 mesh sieve, prepared honeybee
Wax powder；
(2) pelletize: Lac regis apis lyophilized powder, Cera Flava powder, bee pollen, fruit powder mix homogeneously are subsequently adding xylitol, citric acid,
Again with absolute ethyl alcohol and stirring uniformly, 5～20 mesh sieve, and granulate is progressively obtained；
(3) tabletting: granulate is carried out tabletting, thickness is set as 1.2～1.5mm, pressure is set as 15～20kgf, throw after tabletting
Light, gets product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610707244.2A CN106343463A (en) | 2016-08-23 | 2016-08-23 | Royal jelly and beeswax lozenge and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610707244.2A CN106343463A (en) | 2016-08-23 | 2016-08-23 | Royal jelly and beeswax lozenge and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106343463A true CN106343463A (en) | 2017-01-25 |
Family
ID=57843936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610707244.2A Pending CN106343463A (en) | 2016-08-23 | 2016-08-23 | Royal jelly and beeswax lozenge and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106343463A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106993788A (en) * | 2017-03-08 | 2017-08-01 | 北京野馨科技发展有限公司 | All Pure Nature royal jelly lozenge and preparation method thereof |
| CN109430877A (en) * | 2018-11-12 | 2019-03-08 | 上海朴方生物科技有限公司 | A kind of grease lozenge and preparation method thereof |
| CN109601937A (en) * | 2019-02-18 | 2019-04-12 | 付永顺 | A kind of royal jelly pollen composite sheet and preparation method thereof |
| CN112493448A (en) * | 2020-11-30 | 2021-03-16 | 广西医科大学 | Preparation method of fresh royal jelly pills without sucrose |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105725143A (en) * | 2016-02-02 | 2016-07-06 | 桐城市永锦建筑工程有限公司 | Royal jelly lozenge |
-
2016
- 2016-08-23 CN CN201610707244.2A patent/CN106343463A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105725143A (en) * | 2016-02-02 | 2016-07-06 | 桐城市永锦建筑工程有限公司 | Royal jelly lozenge |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106993788A (en) * | 2017-03-08 | 2017-08-01 | 北京野馨科技发展有限公司 | All Pure Nature royal jelly lozenge and preparation method thereof |
| CN109430877A (en) * | 2018-11-12 | 2019-03-08 | 上海朴方生物科技有限公司 | A kind of grease lozenge and preparation method thereof |
| CN109601937A (en) * | 2019-02-18 | 2019-04-12 | 付永顺 | A kind of royal jelly pollen composite sheet and preparation method thereof |
| CN112493448A (en) * | 2020-11-30 | 2021-03-16 | 广西医科大学 | Preparation method of fresh royal jelly pills without sucrose |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101502306B (en) | Bee product composition and preparation method thereof | |
| CN106343463A (en) | Royal jelly and beeswax lozenge and preparation method thereof | |
| CN102512344A (en) | Blumea balsamifera extract, preparation method and application thereof in oral care and clean product | |
| CN103432248B (en) | Health-care product for protecting liver from alcohol damage and nourishing stomach and preparation method thereof | |
| CN106418545A (en) | Functional food with balanced nutrients | |
| CN107094974A (en) | A kind of lycium ruthenicum health-care sweets and preparation method thereof | |
| CN107372985A (en) | One group is adapted to the fructose chocolate using crystal diabetin as sweetener that diabetic population is taken | |
| CN103815111A (en) | Health chuzhou chrysanthemum chewing gum and production method thereof | |
| CN103652692B (en) | Radish leaf nutritional chewable tablet and preparation method | |
| JPH11332527A (en) | Production of extract of edible swallow's nest and health food, cosmetic or the like containing edible bird's nest | |
| CN105685628A (en) | Compound calcium chewable tablets and preparation method thereof | |
| CN101861959A (en) | Pearl nutritional vinegar oral liquid | |
| CN102807411A (en) | Flower-promoting fruit-retention composite fertilizer for Australian nut adult trees | |
| CN102715606A (en) | Beverage | |
| CN103005439B (en) | Bitter gourd compound lipid-lowering oral solution and preparation method thereof | |
| CN104958233A (en) | Toothpaste for cat and preparation method of toothpaste | |
| CN104799277A (en) | Chewable colla corii asini tablet and preparation method thereof | |
| CN109090319A (en) | Newborn mineral salt pressed candy | |
| CN101933567B (en) | Golden pomelo sugar-free mint lozenge and preparation method thereof | |
| CN103750096A (en) | Propolis honey cream rich in plant essence and preparation method thereof | |
| KR20180056878A (en) | Preparations for improving psoriasis and atopy | |
| CN105342923A (en) | Lipstick for preventing lip chapping and its preparation method | |
| CN105250747A (en) | Health maintenance paste | |
| RU2445111C1 (en) | Method for making pumpkin seed oil used for therapeutic, food and cosmetic purposes, and biologically active agent | |
| CN105360539A (en) | Ginger and jujube paste making method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170125 |